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Obesity markedly increases the odds of developing depression. Depressed mood not
only impairs motivation, quality of life and overall functioning but also increases the
risks of obesity complications. Abdominal obesity is a better predictor of depression
and anxiety risk than overall adipose mass. A growing amount of research suggests
that metabolic abnormalities stemming from central obesity that lead to metabolic
disease may also be responsible for the increased incidence of depression in obesity. As
reviewed here, a higher mass of dysfunctional adipose tissue is associated with several
metabolic disturbances that are either directly or indirectly implicated in the control of
emotions and mood. To better comprehend the development of depression in obesity,
this review pulls together select findings addressing the link between adiposity, diet and
negative emotional states and discusses the evidence that alterations in glucocorticoids,
adipose-derived hormones, insulin and inflammatory signaling that are characteristic of
central obesity may be involved.
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INTRODUCTION
Consistent with its broad impact on physiology and health,
obesity is increasingly linked to impairments in central nervous
system (CNS) function. Mood disorders are now well recognized
as significant risks of obesity and related metabolic illnesses.
Obese individuals have about a 55% increased odds of developing
depression (Luppino et al., 2010) whereas diabetes is estimated
to double the incidence of depression (Anderson et al., 2001).
Depression is among the primary causes of disability and its
relentless impact can contribute substantially to the burden
of metabolic disorders. Beyond diminishing quality of life and
functioning, depressed mood presents additional threats to obese
individuals by counteracting adherence to treatment and lifestyle
changes and increasing the risk of complications. Abdominal
adiposity and poor diet quality have been implicated in the devel-
opment of depressed mood during obesity (Roberts et al., 2003;
Dong et al., 2004; Simon et al., 2006; Zhao et al., 2011; Hamer
et al., 2012). There is also a bidirectional association between
obesity and depression such that depressed individuals are more
likely to gain excessive weight due to poor food choices and
reduced physical activity (Luppino et al., 2010; Pan et al., 2012).
Recent work is beginning to illuminate the biological mech-
anisms that promote depressed mood in obesity. This review
focuses specifically on the impact of adiposity, diet and asso-
ciated metabolic signals in the development of depression and
negative emotional states. First, select findings on the influence
of palatable foods, obesity, visceral fat accumulation and dietary
fats on emotional states and depression are presented. With
an aim to shed light on potential mechanisms, we then review
the link between depressive symptomology and some adipose-
related metabolic signals, namely glucocorticoids (GCs), leptin,
adiponectin, resistin, insulin and inflammatory signals. There
are excellent and highly pertinent reviews on the neurobiology
of depression (Nemeroff and Vale, 2005; Krishnan and Nestler,
2008; Willner et al., 2012; Sun et al., 2013) and so this subject will
not be covered here, rather the potential role of metabolic signals
are discussed with regards to what is known about their central
actions to affect anxiety, depressive-like behavior and mood.
MOOD, FOOD, AND ADIPOSITY
Emotions such as joy, frustration and fear can profoundly affect
appetite and food choice. In turn, eating palatable foods can
modify emotional states by producing feelings of comfort, grat-
ification or disgust which can strongly influence our approach or
avoidance of such foods in the future. Positive emotional reac-
tions (i.e., rewarding and hedonic effects) to food are considered
to play a major role in overeating and the development of obe-
sity (Fulton, 2010). External or psychological stressors can have
divergent effects on feeding behavior such that some individuals
increase food intake in response to a stressful experience while
others eat less (Oliver and Wardle, 1999; Gibson, 2006; Dallman,
2010). Similarly, conditions of chronic stress can lead to dimin-
ished appetite and weight loss in some individuals whereas it
can have an opposite effect in others by stimulating consump-
tion of palatable and rewarding foods that blunt stress responses
(Adam and Epel, 2007). For example, a recent study found that
women reporting higher chronic stress with low cortisol reactivity
to an acute social stress test consumed more calories from choco-
late cake and less vegetables than those experiencing low chronic
stress (Tryon et al., 2013). Likewise, a similar positive correlation
between social stress and choice of palatable, energy rich foods
over fruits and vegetables is observed in children (Cartwright
et al., 2003). Stress-induced preference for palatable food has
been documented in several human (Stone and Brownell, 1994;
Epel et al., 2004) and animal studies (Dallman et al., 2003, 2005;
Cottone et al., 2009) while other work demonstrates the effects
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of such foods to dampen signs of stress and anxiety following
exposure to a stressor or conditions of chronic unpredictable
stress (Pecoraro et al., 2004; la Fleur et al., 2005; Maniam and
Morris, 2010; Ulrich-Lai et al., 2010; Finger et al., 2011, 2012).
There is a strong connection between the consumption of high-
fat and high-sugar foods and positive emotions, and despite the
divergence in eating behavior, an overall increase in tasty, energy-
rich foods is reported, independent of stress-induced hyperphagia
or hypophagia (Gibson, 2006; Dallman, 2010).
Mood states such as anxiety and depression can also affect
food choice and energy metabolism. Individuals experiencing
depressed mood show preference for and consumption of palat-
able “comfort foods” and self-report use of these foods as means
to alleviate negative feelings (Macht, 2008). While short-term
consumption of palatable foods can provide relief from negative
emotions and mood states, chronic consumption of calorically-
rich foods and subsequent increases in adiposity may promote
vulnerability to depression and anxiety (Novick et al., 2005;
Simon et al., 2006; Kloiber et al., 2007; Sharma and Fulton,
2013). In a recent study, we found that mice consuming a sat-
urated high-fat diet (HFD) for 12 weeks show depressive-like
features characterized by greater immobility in the forced swim
task and reduced exploratory behavior in elevated plus maze and
open field tests (Sharma and Fulton, 2013). HFD-induced behav-
ioral changes were accompanied by elevated basal hypothalamic-
pituitary-adrenal (HPA) activity and reactivity in response to
stress. Separate findings suggest that negative emotional states
and increased stress sensitivity caused by prolonged high-fat feed-
ing do not rely on severe diet-induced obesity (DIO): six weeks
of saturated HFD, leading to a more moderate gain in weight
(∼11% relative to low-fat diet controls) and without influencing
basal corticosterone levels, produced sucrose anhedonia (reduced
ability to experience pleasure/reward), anxiety-like behavior and
heightened stress-induced HPA activation (Sharma et al., 2012).
Furthermore, when high-fat fed mice were returned to a normal
chow diet craving for sucrose and high-fat food and behavioral
and biochemical signs of anxiety were potentiated (Sharma et al.,
2012). Several groups have shown that removal of a high-fat
or high-sugar diet following prolonged intermittent or regular
intake can increase behavioral and physiological signs of depres-
sion and anxiety (Avena et al., 2008a; Teegarden et al., 2008;
Cottone et al., 2009; Iemolo et al., 2012; Sharma et al., 2012) or
withdrawal (Avena et al., 2008b; Pickering et al., 2009; Sharma
et al., 2012). Results of a new study suggest endocannabinoid sig-
naling in the central nucleus of the amygdala is increased as a
means to counteract increased anxiety elicited by palatable food
withdrawal (Blasio et al., 2013). Thus, not only can chronic high-
fat feeding promote negative emotional states but it may also
enhance sensitivity to stress, including that triggered by diet-
ing, to perpetuate a vicious cycle of overeating, weight gain and
depressed mood.
Evidence suggests that diets high in saturated fat and rela-
tively low in polyunsaturated and monounsaturated fatty acids
contribute to the pathogenesis of both mood and metabolic dis-
orders during obesity. The consumption of foods rich in saturated
and/or trans-fat, like the Western diet, is associated with an
increased incidence of depression whereas diets containingmostly
unsaturated fats, such as theMediterranean diet, appear to reduce
the odds of depression (Sanchez-Villegas andMartinez-Gonzalez,
2013). Other reports indicate that inadequate dietary polyunsat-
urated fatty acids (PUFA) are associated with a higher incidence
of depression (Peet et al., 1998) and that increasing omega-3
PUFA by greater consumption of fish can either decrease depres-
sive symptoms in humans (Lin and Su, 2007; Sanchez-Villegas
et al., 2007; Oddy et al., 2011; Park et al., 2012a) and rodents
(Moranis et al., 2012; Park et al., 2012b) or have no effect on
mood (Ruusunen et al., 2011). A considerable amount of data
shows that diets rich in saturated fatty acids are associated with
increases in overall adiposity and bias fat accumulation in abdom-
inal stores. As compared to individuals on a Mediterranean diet,
those consuming a diet high in saturated fat have increased weight
gain, a greater volume of visceral adipose tissue, larger waist cir-
cumference and more cardiovascular disease mortality (Schulze
et al., 2006; Molenaar et al., 2009; Romaguera et al., 2009, 2010;
Mozaffarian et al., 2011; Estruch et al., 2013; Nazare et al., 2013).
The accumulation of adipose tissue in abdominal stores is more
important than the total amount of body fat in predicting the risk
of several complications of obesity including insulin resistance
and the metabolic syndrome (cluster of metabolic abnormalities
and cardiovascular risk factors with impaired insulin sensitiv-
ity) (Despres and Lemieux, 2006; Tchernof and Despres, 2013)
whereas the Mediterranean diet has been shown to be largely
protective against these metabolic risks (Riccardi and Rivellese,
2000). The higher mass of dysfunctional adipose tissue in obe-
sity may not only cause or exacerbate metabolic abnormalities
that give rise tometabolic disease but also neurobiological impair-
ments that give rise to mood disorders. Indeed, central adiposity
is a better predictor of depression and anxiety risk than body
weight or body mass index (BMI) (Weber-Hamann et al., 2002;
van Reedt Dortland et al., 2013a). These findings suggest that
excessive saturated fat intake and metabolic alterations that pro-
duce or arise from high abdominal fat mass may serve as common
causal elements for both metabolic and mood disorders.
Apart from stimulating visceral fat accumulation, saturated
fat intake increases circulating concentrations of fatty acids like
palmitate which can enter the brain to have deleterious effects
on neural functions. Indeed, palmitate has been shown to impair
leptin and insulin receptor signal transduction in the hypothala-
mus to thereby reduce their catabolic actions and promote weight
gain (Benoit et al., 2009; Kleinridders et al., 2009). As described
below, leptin and insulin are implicated in enhanced mood and
thus it is conceivable that reduced responses to these hormones
elicited by saturated high fat feeding could contribute to negative
emotional states. Supporting the possibility that high CNS palmi-
tate levels modulate neural mechanisms controlling emotions, a
recent study demonstrates that serum concentrations of palmi-
tate correlated positively with depression in humans (Tsuboi et al.,
2013). In addition, we recently found that male adult Wistar
rats consuming a palm oil HFD for 8 weeks and with higher
serum levels of palmitate show greater anxiety-like behavior in
an open field test relative to rats consuming an isocaloric olive oil
HFD (Hryhorczuk et al., unpublished). Interestingly, these effects
were not accompanied by changes in body weight, glycemia and
plasma leptin and insulin levels suggesting that the anxiogenic
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phenotype could be related to the effects of saturated fats to stim-
ulate HPA disturbances and/or inflammation. As elaborated in
the next section, visceral fat deposition and dyslipidemia are asso-
ciated with several endocrine and metabolic changes that have
been implicated in the CNS control of emotional states andmood.
METABOLIC SIGNALS AND EMOTIONAL STATES
A meta-analysis of longitudinal data figures obesity (BMI ≥ 30)
to increase the overall risk of onset of depression by 55% in
Americans while overweight (BMI 25–29.9) to heighten the inci-
dence of depression by 27% (Luppino et al., 2010). Despite the
comorbidity of obesity and depression, it is important to note
that obese individuals classified as “metabolically healthy,” that is
without associated cardiometabolic risk factors (high blood pres-
sure, reduced high-density lipoprotein cholesterol and increased
triglycerides, glycated haemoglobin and C-reactive protein), do
not appear to have a heightened risk for depression (Hamer
et al., 2012). Accordingly, an increasing amount of data points
toward unhealthy diet, visceral adiposity and associatedmetabolic
changes as culprits in obesity-induced depression (Roberts et al.,
2003; Dong et al., 2004; Simon et al., 2006). As discussed here and
summarized in Figure 1, several endocrine and metabolic abnor-
malities have been linked to depressed mood or depressive-like
behavior including hypercortisolemia, insulin and leptin resis-
tance and metabolic inflammatory signals. These signals are
positively associated with central fat accumulation and thus are
important candidate molecules tying obesity to depression.
GLUCOCORTICOIDS
HPA axis dysfunction and elevated GCs are implicated in the
pathophysiology of both obesity and depression. GCs exert
pleiotropic effects on metabolic, endocrine, immune and behav-
ioral functions. Under normal physiological conditions of acute
stress, the HPA axis is activated to release GCs which have an
adaptive value to restore energy balance by increasing insulin,
motivation for palatable food (Piazza and LeMoal, 1997; Dallman
et al., 2006; Dallman, 2010) and mobilizing stored energy and
directing it to central stores (Mann and Thakore, 1999). The
critical actions of GCs on adipose tissue deposition were demon-
strated by early studies showing that adrenalectomy prevents
obesity in Zucker rats and this is reversed by replacement of
corticosterone (Freedman et al., 1985; Castonguay et al., 1986).
Fat mass is associated with increased cortisol rise at the time
of waking and high cortisol reactivity under stressful situations
(Therrien et al., 2007, 2008; Mujica-Parodi et al., 2009). But while
cortisol production and turnover are increased in obesity, over-
all systemic cortisol levels have been shown to be normal or low
in obesity (Hautanen et al., 1997). Rather, dysregulation of HPA
axis activity is more a function of body fat distribution rather
than total fat mass as abnormal diurnal variation in circulating
cortisol levels is positively associated with the waist-to-hip ratio
(Lasikiewicz et al., 2008). Over-activation of the HPA axis in sub-
jects with abdominal obesity is suggested by elevated response
to corticotrophin releasing hormone (CRH) stimulation, and
increased basal and stimulated response to stress (Pasquali, 2012).
Excess systemic cortisol has been shown to result in a 2- to 5-fold
increase in visceral adipose tissue (Brown et al., 2004), and as such
FIGURE 1 | Metabolic signals and disturbances linking obesity and
abdominal adiposity with depression. Central obesity and related
metabolic changes correlate positively with depression. Excessive intake of
foods high in saturated fat promotes weight gain, visceral fat accumulation
and increased risk of depressed mood. Endocrine changes associated with
abdominal obesity include hypothalamic-pituitary-adrenal (HPA)
dysregulation and altered plasma levels of cortisol, leptin, adiponectin,
resistin and insulin—hormones implicated in the central control of emotion
and mood. Obesity-induced impairments in brain glucocorticoids (GCs),
leptin and insulin receptor signaling are posited to link hypercortisolemia
and leptin and insulin resistance to depression. Central fat accumulation
also stimulates the release of inflammatory cytokines (e.g., tumour
necrosis factor-α, interleukin-1β) and signals (C-reactive protein) that can
promote neuroinflammatory responses and depressive behavior. Increased
entry of saturated free fatty acids into the brain may also propagate
neuroinflammation, leptin/insulin resistance and, consequently, depression.
In parallel, increased vulnerability to external stressors, negative emotional
states and adverse cognitive style (e.g., poor self-image) associated with
overweight and obesity can potentiate consumption of energy-dense
“comfort” foods to fuel a vicious cycle of central obesity, metabolic
dysfunction and depression. This figure was produced using Servier
Medical Art.
individuals under chronic stress are likely to havemore visceral fat
(Adam and Epel, 2007; Kyrou and Tsigos, 2009).
Studies have found small elevations in serum cortisol concen-
trations associated with depression (Parker et al., 2003; Raison
and Miller, 2003; Stetler and Miller, 2011). Further, individuals
with Cushing’s syndrome (characterized by cortisol hypersecre-
tion and abdominal obesity) exhibit behavioral and neurobiolog-
ical features of depression (Sonino et al., 1998). GCs not only
act peripherally to maintain energy homeostasis but also feed-
back to the CNS to modulate HPA activity and the emotional
and behavioral effects of stress (Herman et al., 2003). GCs are
known to target GC receptors [includingmineralocorticoid (MC)
receptors] in midbrain and limbic circuits that regulate reward
and emotional processes (Arnett et al., 2011; Solomon et al.,
2012; Wang et al., 2013). Repeated administration of corticos-
terone to rodents is reported to produce depressive-like behavior
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(Kalynchuk et al., 2004; Gregus et al., 2005) whereas GC receptor
overexpression in the forebrain increases depressive-like behavior
in the forced swim test and anxiety-like behavior in the elevated
plus maze task (Wei et al., 2004). In contrast, loss of forebrain GC
receptors has also been shown to increase depressive-like behavior
in the forced swim and tail suspension tasks (Boyle et al., 2005)
and increase stress-induced locomotor activation (Boyle et al.,
2006). Finally, suggesting a particular role for MC receptor sig-
naling in anxiety, MC receptor overexpression in the forebrain
(Rozeboom et al., 2007) or specifically in basolateral amygdala
(Mitra et al., 2009) reduces anxiety-like behavior. These con-
tradictory results may be reconciled by findings that increasing
forebrain GR receptor signaling enhances the magnitude of both
positive and negative emotional responses depending upon the
test employed suggesting that GC are important for “emotional
lability” (Wei et al., 2004). On the whole, however, many findings
support a pro-depressive effect of GC surplus, especially in the
context of their strong influence to inhibit brain development and
growth. Excess GCs promote hippocampal atrophy and decrease
neurogenesis in the hippocampus—actions that have been well-
implicated in the effect of GC on depressive behavior (McEwen,
1997; Bremner, 2006; Goebel et al., 2010; Schoenfeld and Gould,
2012).
It is important to note that hypercortisolism is often associ-
ated with melancholic depression, a subtype of clinical depression
that is accompanied by anhedonia, hypophagia and weight loss;
while atypical depression, the most common form of depres-
sion, is characterized by reduced HPA activity, improved mood in
response to positive events and increased appetite, carbohydrate
craving and frequently weight gain (Juruena and Cleare, 2007).
Despite these categorizations, there is evidence of an association
between hypercortisolemic depression and abdominal fat accu-
mulation (Weber-Hamann et al., 2002). Hypercortisolemia in
depressed individuals is accompanied by decreased GC-mediated
negative feedback and increased release of CRH from the par-
aventricular nucleus (PVN) (Holsboer, 2000). Along these lines,
we found that the increased anxiety-like behavior of the rats sub-
jected to the saturated palm oil HFDwas accompanied by elevated
basal corticosterone levels and reduced GC-mediated negative
feedback (dexamethasone suppression test) relative to rats con-
suming the calorically-matched olive oil HFD (Hryhorczuk et al.,
unpublished). As no differences in weight, leptin, insulin and
blood glucose were detected, we hypothesize that increased cor-
ticosterone and/or reduced GC receptor signaling in limbic areas
may in part mediate the effects of a saturated HFD to elicit
negative emotional states. It is interesting to speculate that GC
surplus in obesity may be associated with central impairments
in the intracellular metabolism of GCs by 11β-hydroxysteroid
dehydrogenases (11β-HSDs), enzymes that are well-implicated
in visceral fat accumulation and affiliated peripheral metabolic
abnormalities such as insulin resistance (Tchernof and Despres,
2013). 11βHSDs are widely expressed in the brain, including
the hippocampus and amygdala, and are linked to changes in
emotional and cognitive functions (Wyrwoll et al., 2011). It is
clear that HPA abnormalities serve as common elements in the
pathophysiology of both obesity and depression, but their direct
contribution to emotional disturbances elicited by DIO have not
been established. Notably, the data collectively suggest that diets
rich in saturated fat and visceral fat accumulation, but not body
mass per se, are important mediators of HPA disturbances and
depressive symptomology associated with obesity.
ADIPOSE-DERIVED HORMONES
Leptin
As an endocrine organ, adipose tissue secretes numerous pep-
tide hormones that target the brain and other tissues to regulate
metabolism and behavior. Leptin is an adipokine that circulates in
proportion to the size of the fat mass (Maffei et al., 1995). Apart
from its numerous actions on physiological processes such as
appetite, energy expenditure and neuroendocrine function, lep-
tin is linked to human depression and has been shown to have
antidepressant and anxiolytic effects in rodents (Asakawa et al.,
2003; Liu et al., 2010b; Yamada et al., 2011). Epidemiological find-
ings on leptin levels and depression are conflicting. Several studies
find that individuals with major depressive disorder (MDD) have
lower plasma leptin levels compared to healthy controls with sim-
ilar BMI (Kraus et al., 2001; Atmaca et al., 2002, 2008; Westling
et al., 2004; Jow et al., 2006). However, other reports show that
plasma leptin levels are increased in women with depressive dis-
order (Rubin et al., 2002; Esel et al., 2005; Zeman et al., 2009)
and that leptin levels are either increased (Kraus et al., 2002;
Esel et al., 2005; Schilling et al., 2013) or not changed (Kraus
et al., 2002; Schilling et al., 2013) by antidepressant treatment. In
depressed individuals suffering from loss of appetite plasma leptin
concentrations were reported not to differ from those of healthy
controls (Deuschle et al., 1996) whereas another study found
higher serum leptin only in atypical depressive patients in which
increased appetite is often observed (Gecici et al., 2005). In older
men, the combination of elevated visceral fat and high leptin lev-
els was associated with depression onset (Milaneschi et al., 2012).
Rodent studies, on the other hand, present more conclusive find-
ings. Lack of leptin (obese ob/obmice) or its receptor (obese db/db
mice) is associated with increased behavioral despair in the forced
swim task (Collin et al., 2000; Sharma et al., 2010; Yamada et al.,
2011). Repeated leptin treatment has also been shown to reduce
anxiety in ob/ob mice (Asakawa et al., 2003). Systemic or central
leptin administration in normal mice has antidepressant effects as
measured by the tail suspension test, forced swim task and social
interaction test and has anxiolytic effects in the elevated plusmaze
(Liu et al., 2010a; Yamada et al., 2011). In sum, a greater part of
the human research ties low leptin levels to depression but there
is discordancy amongst these investigations which may be a func-
tion of the subtype of depression, the age and sex of participants
and perhaps, as elaborated below, the onset of leptin insensitivity
generated by high leptin levels.
One of the ways in which leptin may affect emotions is via
its influence on HPA activity. A negative correlation between
basal concentrations of leptin and mobilization of cortisol is
reported in humans (Komorowski et al., 2000). Leptin defi-
cient ob/ob mice have elevated corticosterone which is reduced
by leptin replacement (Garthwaite et al., 1980; Arvaniti et al.,
2001). Systemic leptin administration lowers corticosterone lev-
els and prevents the induction of CRH synthesis in the PVN
and the activation of CRH neurons observed in food-deprived
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ob/ob mice (Huang et al., 1998). In turn, chronic unpredictable
mild stress in rats which leads to depressive-like behaviors acti-
vates the HPA axis and decreases serum leptin levels (Ge et al.,
2013). Beyond modulating HPA activity, leptin also targets the
long-form of its receptor (LepRb) in midbrain and forebrain loci
to affect emotional processes. Leptin has antidepressant effects
when administered into the hippocampus, an area mediating cog-
nitive impairments of depression whereas genetic deletion of hip-
pocampal LepRb results in a depression-like phenotype (Asakawa
et al., 2003; Lu et al., 2006; Finger et al., 2010; Liu et al., 2010a;
Guo et al., 2013). Loss of LepRb specifically in glutamatergic neu-
rons of the forebrain (mainly hippocampus and prefrontal cortex)
was recently reported to elicit depressive-like behavior without
affecting anxiety (Guo et al., 2012). Leptin also functionally acti-
vates dopamine neurons in the ventral tegmental area (VTA) of
the midbrain where it reduces dopamine neuronal firing while
increasing dopamine availability (Fulton et al., 2006; Hommel
et al., 2006). Selective deletion of LepRb frommidbrain dopamine
neurons has been shown to increase anxiety-like behavior, but not
depressive-like behavior, in several behavioral tests via increased
D1 receptor signaling in the central nucleus of the amygdala
(Liu et al., 2011). Finally, recent work shows that leptin levels
are positively associated with stress-induced dopamine release
(Burghardt et al., 2012). Collectively, the data demonstrates that
the antidepressant actions of leptin are mediated by LepRb sig-
naling in limbic and prefrontal nuclei whereas leptin action in
dopamine neurons of the ventral midbrain that innervate the cen-
tral nucleus of the amygdala underlie the anxiolytic actions of
leptin.
Leptin levels are associated with risk of depression onset
in men with a significant amount of visceral fat (Milaneschi
et al., 2012) and correlate positively with depressive symptoms in
patients with type 2 diabetes (Labad et al., 2012). In conditions of
obesity, and particularly central obesity that favors insulin resis-
tance and type 2 diabetes, leptin sensitivity is diminished owing to
lower CNS leptin entry (decreased CSF: plasma leptin ratio) and
defective LepRb signaling (Myers et al., 2012). This phenomenon
known as leptin resistance is characteristic of obesity and may
explain how the risk of mood disorders is elevated in obese states
associated with high circulating leptin levels. Compatible with
this notion, mice rendered obese by a HFD show reduced sen-
sitivity to the antidepressant actions of leptin and to the effects of
leptin to increase hippocampal brain-derived neurotrophic factor
(BDNF) concentrations (protective against depression) relative to
low-fat diet controls (Yamada et al., 2011). Further, leptin insen-
sitivity may exacerbate HPA dysregulation in obesity (Collura
et al., 2009) and thereby enhance the mass of dysfunctional cen-
tral adipose stores in a cortisol-dependent manner. Features of
leptin resistance have been reported in the midbrain VTA where
mesolimbic DA neurons reside (Matheny et al., 2011), although
it is not yet known whether or not reduced leptin sensitivity in
this region has anxiogenic effects as one would predict. Leptin
resistance would appear to affect multiple neural and endocrine
pathways that affect emotions and mood including hippocam-
pal and mesolimbic dopamine pathways and HPA activity, and
thus represents another strong candidate mechanism underlying
depression in obesity.
Adiponectin
Adiponectin is another adipose-derived hormone that is well
implicated in energy homeostasis and insulin resistance (Turer
and Scherer, 2012) and that has more recently been tied to depres-
sion. While plasma adiponectin is found at high concentrations
in healthy subjects it often correlates negatively with obesity, waist
circumference and visceral fat in humans (Arita et al., 1999; Cnop
et al., 2003; Ryo et al., 2004; Hanley et al., 2007; Cohen et al., 2011;
Mente et al., 2013) and rodents (Maeda et al., 2001; Milan et al.,
2002; Delporte et al., 2004; Ye et al., 2007). However, metabol-
ically healthy obese subjects have plasma levels of adiponectin
similar to lean controls (Aguilar-Salinas et al., 2008; Morrison
et al., 2011; Doumatey et al., 2012) suggesting that adiponectin
levels changes are secondary to metabolic disturbances found in
obesity. In humans, plasma adiponectin levels are reported to
negatively correlate with depressive measures in patients with
MDD and in women with depressive disorder (Zeman et al.,
2009). Alternatively, other studies report a positive relationship
between adiponectin levels and depressive and anxiety symptoms
(Wilhelm et al., 2013) and men with subsyndromal depression
(Jeong et al., 2012); or no change in patients with MDD (Jeong
et al., 2012). Antidepressant therapy in individuals with MDD
does not appear to affect adiponectin and resistin levels (Lehto
et al., 2010). Recent work shows that chronic social defeat in
mice decreases the level of plasma adiponectin and that recapitu-
lating low levels of adiponectin by using haploinsufficient mice
(Adipo±) increases the incidence of stress-induced depressive-
like behaviors due to impaired HPA axis negative feedback (Liu
et al., 2012). Moreover, it was found that, like leptin, cen-
tral administration of adiponectin has antidepressant effects as
assessed in the forced swim test and tail suspension test (Liu et al.,
2012). In summary, while animal studies suggest an antidepres-
sant action of adiponectin, the link between plasma adiponectin
concentrations and depression in humans is less clear which may
be connected to the type of depressive disorder and the effects of
sex and antidepressant treatment.
Resistin
Adipocyte-derived resistin is linked to insulin resistance in rodent
models, however, human resistin is released from macrophages
and its association with cardiometabolic disease is less defined
(Schwartz and Lazar, 2011). Plasma resistin levels in relation to
obesity are not as clear as those for adiponectin. Early studies
found that circulating resistin levels are elevated in genetic and
DIO in mice (Steppan et al., 2001) and obese humans (Degawa-
Yamauchi et al., 2003; Owecki et al., 2011; Sadashiv et al., 2012)
whereas other studies found that resistin is downregulated in
human obesity (Way et al., 2001; Ye et al., 2013) and rodent
obesity (Milan et al., 2002; Maebuchi et al., 2003). As for the
relationship between resistin and depression in humans, resistin
levels were found to be positively correlated with atypical but not
typical depression (Lehto et al., 2010). In addition, human resistin
levels were positively linked with salivary cortisol in depressed
patients (Weber-Hamann et al., 2007) which is in line with a study
reporting higher plasma resistin levels in women suffering from
Cushing’s syndrome (Krsek et al., 2004). Conversely, resistin lev-
els are lower in patients receiving antidepressant treatment who
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have remitted from depression (Weber-Hamann et al., 2007). As
it currently stands, there are no documented reports exploring
the impact of resistin treatment or its loss of function in ani-
mal studies of anxiety and depression. The epidemiological data
would predict resistin treatment to have pro-depressant actions,
a potential finding that could be related to resistin’s status as an
inflammatory marker.
INSULIN
Depression is at least twice as common among those with
diabetes and is associated with a more unfavorable prognosis
(Anderson et al., 2001). Depression often appears at the predi-
abetes stage which is marked by insulin resistance (Kan et al.,
2013). Individuals with insulin resistance that are overweight or
obese (Platt et al., 2013), with metabolic syndrome (Koponen
et al., 2008; Akbaraly et al., 2009; Almeida et al., 2009; Pulkki-
Raback et al., 2009) or with abdominal obesity andmetabolic syn-
drome (Hamer et al., 2012) are more likely to develop depression.
However, some literature points toward little or no association
between metabolic syndrome/insulin resistance and depression
(Adriaanse et al., 2006; Platt et al., 2013; Shen and Bergquist-
Beringer, 2013). A recent systematic review and meta-analysis
found a small but significant cross-sectional association between
depression and insulin resistance (Kan et al., 2013). Another
recent study found that treating patients with MDD and abdom-
inal obesity or metabolic syndrome with the insulin-sensitizing
drug pioglitazone for 12 weeks alone or in combination with
an antidepressant therapy reduced signs of depression and anx-
iety (Kemp et al., 2012). Attenuation of depressive symptoms
correlated positively with the reduction in insulin resistance.
Similarly, rosiglitazone administered to normal chow-fed mice
and rats was reported to decrease immobility time in tail sus-
pension and forced swim tests suggestive of an antidepressant
action (Eissa Ahmed et al., 2009). Collectively, the data suggest
that insulin resistance may be causal to depressed mood during
obesity while increasing sensitivity to insulin has antidepressant
actions.
Several studies have sought to determine the role of CNS
insulin in the control of emotional states. Third ventricle injec-
tion of an insulin receptor antisense RNA in rats was reported
to stimulate depressive-like behavior by increasing immobility
in forced swim test and decreasing open arm entries in ele-
vated plus maze (Grillo et al., 2011). Intranasal insulin treatment
provides a means to deliver insulin to the brain by bypassing
the blood–brain barrier. Daily intranasal insulin treatment for
8 weeks in healthy men was shown to ameliorate self-reported
mood (Benedict et al., 2004). Other clinical studies show that
intranasal insulin reduces cortisol levels and thus may have
antidepressant actions by lessening visceral obesity (Chapman
et al., 2013). Intranasal insulin delivery in mice for 7 days
was shown to have anxiolytic properties in the light/dark box
test, but insulin did not have any effect on anxiety behavior
in the marble-burying test and elevated plus maze. In predi-
abetic (hyperglycaemic and hyperinsulinemic) mice fed for 55
weeks with a 30% kcal fat diet, the anxiolytic effects of intranasal
insulin are somewhat diminished (Marks et al., 2009): intranasal
insulin failed to reverse the anxiogenic effects of DIO in the
light/dark box test while it attenuated anxiety in the elevated
plus maze and the marble-burying test. These data suggest that
DIO may provoke increased anxiety through impairments in
central insulin signaling. In support of this possibility, chronic
intake of HFD elicits impairments in hypothalamic insulin recep-
tor signaling (De Souza et al., 2005) and similar resistance to
insulin is documented in other brain areas (Kim and Feldman,
2012). By and large, available evidence suggests that insulin has
mood-enhancing effects or point to a positive correlation between
insulin resistance and depression. However, it will be important
to determine if intranasal insulin has antidepressant effects in
depressed individuals and, if so, whether this action is maintained
in obesity. In addition, more research is required to identify the
brain sites mediating the effects of insulin on mood. One likely
site of action is the VTA as recent evidence demonstrates that
insulin inhibits excitatory glutamatergic inputs onto dopamine
neurons (Labouebe et al., 2013). In view of leptin’s actions to
diminish behavioral despair and anxiety via hippocampal and
ventral midbrain nuclei, respectively, regions where insulin recep-
tors are also expressed, it is interesting to speculate that these
sites could be important for an influence of insulin on emotional
states.
INFLAMMATORY SIGNALS
Obesity is characterized by a state of prolonged low-grade
inflammation and several lines of evidence implicate immune-
mediated tissue inflammation as an important element link-
ing obesity to insulin resistance. Likewise, numerous findings
implicate immune activation in the pathogenesis of depres-
sion (Dunn et al., 2005; Dantzer et al., 2008). Elevated levels
of inflammatory signals have been associated with the sever-
ity of depression (Levine et al., 1999; Dunn et al., 2005). In
addition, cancer patients receiving cytokine treatment are more
likely to experience depressive symptoms (Musselman et al.,
2001). Cytokines are important mediators of innate and adap-
tive immunity. Both peripherally- and centrally-derived cytokines
can stimulate CNS cytokine receptors and several findings point
to cytokines as strong modulators of mood. Administration
of lipopolysaccharide generates the release of interleukin 1β
(IL1β) and tumour-necrosis factor-alpha (TNFα) in the brain to
produce sickness behaviors characterized by social withdrawal,
decreased exploratory behavior and depressive-like symptoms
(Dunn et al., 2005). Direct administration of IL1β and TNFα
(but not IL6) to the brain produces depressive symptomology
in rodents (Goshen et al., 2008) whereas central administra-
tion of an IL1β receptor antagonist during chronic stress (Koo
and Duman, 2008) or targeted deletion of the gene encod-
ing TNFα produces antidepressant like effects (Simen et al.,
2006). Similarly, preclinical studies show that blocking pro-
inflammatory cytokine signaling can produce an antidepres-
sant effect. An important transcriptional target of IL1β and
other cytokines is the inhibitor of nuclear factor kappa B
kinase (IκK)/nuclear factor kappa B (NFκB) pathway. Activation
of IκK/NFκB specifically in the nucleus accumbens (NAc), a
region viewed to mediate hedonic deficits in depression, using
viral-mediated gene transfer was shown to increase anxiety-
and depressive-like behavior using the openfield and forced
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swim tests, respectively (Koo et al., 2010). In contrast, inhibi-
tion of IκK/NFκB in the NAc decreased depressive-like behav-
ior (Christoffel et al., 2012). Together, these findings suggest
that elevated levels of pro-inflammatory cytokines in the brain
and NAc IκK/NFκB signaling increases anxiety and depressive
symptomology.
Obesity provides a means by which inflammatory responses
in the brain can be generated. Consistent with this view, a recent
study demonstrates that several gene markers of neuroinflamma-
tion are upregulated in the hypothalamus of rodents during high-
fat feeding including IL6, TNFα, IKKβ and NFκB (Thaler et al.,
2012). This metabolic inflammatory response in the hypothala-
mus appeared rapidly after the onset of high-fat feeding, waned
and then escalated in magnitude and diversity during chronic
high-fat feeding. Increased infiltration, activation and prolifera-
tion of microglia and astrocytes, called reactive gliosis, was also
noted in rodents following 4 weeks of high-fat feeding along
with similar postmortem signs of gliosis and neuronal injury
in the hypothalami of obese individuals (Thaler et al., 2012).
At a functional level, elevated inflammatory conditions in the
hypothalamus have been shown to contribute to leptin resistance
(Kleinridders et al., 2009), insulin resistance (De Souza et al.,
2005) and to neuroendocrine impairments, obesity and glucose
intolerance in a manner that depends on IKKβ/NFκB signaling
(Zhang et al., 2008).
A recent, large-scale epidemiological study evaluated the
impact of HPA activity, autonomic nervous system, inflamma-
tion and lifestyle factors on adverse associations of anxiety and
depression severity with high and low-density lipoprotein choles-
terol, triglycerides, BMI and waist circumference. Interestingly,
the inflammatory marker C-reactive protein (CRP) had the most
consistent impact explaining 14–53% of the associations of anxi-
ety and depression severity with abdominal obesity and dyslipi-
demia (van Reedt Dortland et al., 2013b). In a separate study,
men with low-grade inflammation, high CRP levels and depres-
sive symptoms were more likely to develop abdominal obesity
during the 11-year follow-up (Valtonen et al., 2012). In addi-
tion, individuals with diabetes and MDD were found to have
significantly higher CRP levels than non-diabetic patients with
depression (Alvarez et al., 2013). A new epidemiological study
showed that obesity is associated with greater depressive symp-
toms and that CRP concentrations were independently associated
with depression scores in analyses fully adjusted for sociodemo-
graphic and background variables (Daly, 2013). Finally, another
recent and large epidemiological study of men and women aged
20–100 years observed that increasing CRP levels were associ-
ated with increasing risk for psychological distress and depression
(Wium-Andersen et al., 2013). Interestingly, increased CRP lev-
els have been show to exacerbate injury-induced gliosis in the
brain (Hsuchou et al., 2012b). It is intriguing to speculate whether
or not potentiation of injury-induced gliosis by CRP is due in
part to its actions to increase blood-brain barrier permeability to
noxious stimuli (Hsuchou et al., 2012a). Decreasing the perme-
ability of the BBB to free fatty acids, cytokines and/or immune
cells are avenues through which abdominal obesity and dyslipi-
demia can encourage neuroinflammation and subsequent mood
impairments.
SUMMARY AND PERSPECTIVES
Obesity is largely driven by excessive energy intake which is a
product of both the amount and caloric density of food con-
sumed. Agricultural, economic and cultural factors contribute to
an abundance of energy-rich and palatable foods in many parts of
the Western world and favor the selection of products containing
saturated oils and refined sugars. The psychological dynamics of
the consumer weigh heavily at the food selection level. Emotional
reactions to food can largely affect our future intake and can pro-
pel overeating. What is becoming increasingly evident is that,
in turn, the nutrients we consume can over time influence our
mood and behavior either via direct CNS actions or by their
impact on energymetabolism, endocrine function and immunity.
Findings from several fronts tie the development of depressed
mood in obese individuals to overeating, central adipose mass
and associated metabolic disruptions (Figure 1). Recent research
findings propose that the overconsumption of saturated fats is a
potential factor underlying obesity-induced depression. In view
of the effect saturated fats to bias central fat deposition and
the association between saturated fat intake and cardiometabolic
(Micha and Mozaffarian, 2009, 2010) and neurological diseases
(Takechi et al., 2010; Kanoski and Davidson, 2011), the link
between saturated fats and depression is not surprising. Thus,
to further our understanding of the development of depression
during obesity we can build upon a wealth of knowledge about
the metabolic disturbances associated with central obesity, how
these disturbances affect signaling mechanisms and, while less
vast, our expanding understanding of how these signals modu-
late neural functions. Identifying the root causes of depression
during obesity will greatly benefit from much more neurobio-
logical and behavioral research of the mood-regulating CNS sites
and mechanisms through which metabolic, inflammatory and
nutrient signals act.
Endocrine abnormalities are common in visceral obesity. As
discussed, various findings suggest that alterations in cortisol,
leptin, adiponectin and resistin levels are associated with depres-
sion and/or that these hormones have CNS actions to affect
mood, anxiety and depressive-like behavior. Another hormone
well-implicated in overeating an obesity development is the gut
peptide ghrelin, and several studies suggest that ghrelin plays a
key role at the interface of homeostatic control and neural cir-
cuits involved in reward and stress (for review see Abizaid article in
this issue). We did not review a role for ghrelin, however, because
there is currently no evidence specifically linking this hormone to
depression. On the other hand, neuropeptide systems that intri-
cately interact with metabolic hormones have been linked to the
pathophysiology of mood disorders (for review see Mathe et al.,
2007). For example, apart from its orexigenic action, neuropep-
tide Y (NPY) was shown to reduce signs of anxiety when injected
centrally (Heilig et al., 1989; Heilig, 1995). In line with these
earlier studies, recent work demonstrates that NPY mRNA lev-
els were decreased in hippocampal homogenates of a rat genetic
model of depression (Melas et al., 2013). NPY is also reduced in
the CSF of patients with depressive disorder (Heilig et al., 2004)
and this is reversed upon antidepressant therapy (Nikisch et al.,
2005). Yet other central signaling molecules with strong ties to
both energy metabolism and emotions are the endocannabinoids.
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A role for endocannabinoid signaling via the CB1 receptor in
anxiety and depressive symptoms is well established (Mangieri
and Piomelli, 2007; Gorzalka and Hill, 2011). A recent study
demonstrates the importance of endocannabinoid signaling in
the amygdala in the anxiogenic effects of palatable food with-
drawal (Mangieri and Piomelli, 2007; Gorzalka and Hill, 2011;
McLaughlin and Gobbi, 2012; Mechoulam and Parker, 2013) and
thus add to the growing evidence that endocannabinoids may be
another link between obesity and mood disorders.
Endocrine dysfunction in central obesity typically coincides
with a mild inflammatory state. Central adipose stores are a
source of inflammatory cytokines secreted by local monocytes
and macrophages, and the release of another inflammatory
molecule, CRP, is upregulated during obesity and inflammation.
Several findings demonstrate the pro-depressive effects of inflam-
matory signals whereas others studies are uncovering the deleteri-
ous impact of hypothalamic inflammation brought on by DIO. At
present, the mechanisms that initiate and propagate neuroinflam-
mation during high-fat feeding are not fully known. Moreover,
it is not clear if limbic regions controlling emotions and mood
also succumb to this “metabolic inflammation” during high-fat
feeding. It also remains to be established if immune cells that
are activated during obesity can infiltrate the brain as they do in
other chronic inflammatory conditions and thereby contribute to
the neuroinflammatory response. Apart from the involvement of
humoral factors, one should also consider the action of metabolic
signals on vagal efferents to the CNS. Cytokine stimulation of
vagal nerves can trigger neuroinflammatory responses (Capuron
and Miller, 2011) and therefore may prove to be an impor-
tant pathway to diet-induced neuroinflammation. Establishing
the direct impact of these metabolic and inflammatory signals
to obesity-induced depression will not prove easy as they are
often interconnected and temporally overlap. To surmount such
difficulties controlled animal studies employing conditional and
time-resolved loss- or gain-of-function strategies will be very
valuable for determining the distinct involvement of each of these
factors in the development of depressive behavior during high-fat
feeding and obesity.
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